Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property Routine +

Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

Curium Advances Japan Radiopharma Pipeline as Phase 2 Dosing Completes for 64Cu-PSMA-I&T

By The Northwire Desk — AI Analysis Jun 11, 2026 · 03:04 4587 NaN
Executive Summary
  • On June 11, 2026, Curium Group announced the completion of patient dosing in a registrational Phase 2 clinical trial for 64Cu-PSMA-I&T, a diagnostic PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) in Japanese patients.
  • The trial is an open-label, single-arm study evaluating sensitivity, specificity, and safety in newly diagnosed unfavorable intermediate, high, or very high-risk prostate cancer patients scheduled for prostatectomy with pelvic lymph node dissection.
  • Results will be combined with Curium’s global clinical data to support a future regulatory submission in Japan.
  • A parallel registrational trial for the therapeutic counterpart, 177Lu-PSMA-I&T, is advancing to evaluate efficacy and safety in metastatic castration-resistant prostate cancer (mCRPC).
  • The Japan program is executed via a partnership with PeptiDream and its subsidiary PDRadiopharma, which leads local regulatory filing, manufacturing, and commercialization. Curium leads global development and will support technology transfer for a high-throughput Copper-64 manufacturing line.
  • Global pipeline context includes a Phase 3 ECLIPSE trial for 177Lu-PSMA-I&T that already met its primary endpoint, alongside ongoing Phase 3 SOLAR trials for 64Cu-PSMA-I&T in biochemical recurrence and newly diagnosed high-risk cohorts.
Material Impact
  • The announcement represents a standard clinical development milestone rather than a commercial or financial inflection point.
  • Completion of dosing is a necessary step toward data readout and regulatory filing, but it does not guarantee efficacy, safety, or market approval.
  • The strategic value lies in the theranostic pairing (diagnostic 64Cu + therapeutic 177Lu) and the localized manufacturing/commercialization setup in Japan, which could reduce supply chain friction for short-half-life radiopharmaceuticals.
  • No immediate revenue, margin, or cash flow impact is disclosed. The news is incremental to the existing global clinical program and does not alter the fundamental risk profile of the asset.
4587 · Price
Company Overview
  • Curium Group operates in the radiopharmaceutical and theranostics sector, focusing on diagnostic and therapeutic isotopes for oncology, particularly prostate cancer.
  • The company leverages a dual-track strategy combining imaging agents (64Cu-PSMA-I&T) with targeted radionuclide therapies (177Lu-PSMA-I&T).
  • Strategic partnerships with regional players like PeptiDream/PDRadiopharma indicate a focus on localized commercialization and manufacturing infrastructure, which is critical for radiopharmaceuticals with short isotope half-lives.
  • The business model relies on clinical success, regulatory approvals, and commercial partnerships rather than direct retail sales.
Read the original news release →